Quick Answer
BioNexus Gene Lab Corp reported Net Income Loss of -$1.60 million for the year ending 2024.
- BioNexus Gene Lab Corp showed an increase of +39.2% in Net Income Loss from 2023 to 2024.
- This data is from BioNexus Gene Lab Corp's annual report (Form 10-K), filed with the SEC on April 15, 2025.
- XBRL data for this metric is available from 2018 to 2024 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: $271.9 thousand | Q2 2018: -$39.5 thousand | Q3 2018: -$89.0 thousand | Q1 2019: -$61.5 thousand | Q2 2019: -$70.4 thousand | Q3 2019: -$22.0 thousand | Q1 2020: $1.07 million | Q2 2020: -$35.8 thousand | Q3 2020: $234.5 thousand | Q1 2021: $338.7 thousand | Q2 2021: $28.3 thousand | Q3 2021: $295.3 thousand | Q1 2022: $17.1 thousand | Q2 2022: -$138.7 thousand | Q3 2022: -$77.4 thousand | Q1 2023: -$69.1 thousand | Q2 2023: -$259.3 thousand | Q3 2023: -$2.61 million | Q1 2024: -$103.8 thousand | Q2 2024: $199.1 thousand | Q3 2024: -$1.35 million | Q1 2025: -$623.3 thousand | Q2 2025: -$616.2 thousand | Q3 2025: -$709.0 thousand.
- Over the full 7 years of available data (2018 to 2024), BioNexus Gene Lab Corp's Net Income Loss has declined by 6,142.0%.
- Historical annual values: Fiscal year 2024: -$1.60 million | Fiscal year 2023: -$2.63 million | Fiscal year 2022: -$356.0 thousand | Fiscal year 2021: $751.6 thousand | Fiscal year 2020: $1.09 million | Fiscal year 2019: -$246.5 thousand | Fiscal year 2018: $26.5 thousand.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: